We are delighted to announce a formal partnership with leading Closed Loop Marketing software vendor Agnitio. PharmiWeb Solutions will incorporate Agnitio's software in to its outsourced digital marketing (ODM) portfolio for pharmaceutical corporate customers.

Paul Hartigan, CEO of PharmiWeb Solutions, commented: ‘For some time we've been seeing increasing demand for a closed-loop marketing element to our solutions. We reviewed the market, and felt that Agnitio presented by far the most powerful options for us. By integrating the Agnitio product set into our ODM offering means we can deploy behaviourally targeted, strategic marketing campaigns at either a local or pan-European level. We're really excited about this partnership, and what it means for our customers'

Morten Hjelmsø, Founder and CEO of Agnitio, added: “PharmiWeb were an obvious choice of partner for Agnitio as their understanding of digital and multi channel marketing means they are a perfect fit between content and technology. As Pharma Cos continue to develop their digital strategies it is key that both the platform and partners they choose fully support their needs and creative requirements. We firmly believe the combination of Agnitio and PharmiWeb will further strengthen our growth in the UK and ensure we are best placed to offer the right support and guidance necessary for customers”


This partnership allows us to create a standardised digital marketing platform for brands that can be delivered online (through e-details, websites, and e-learning modules) and face-to-face (e.g. rep-led) - with live customer profiling and reporting capabilities. And we can fully integrate in to any CRM environment.

The uniquely flexibility of our solution means that we can deliver personalised, highly engaging messaging for all customer profiles. And that means a proven positive impact on prescribing behaviour, high message recall, increased call length, and a detailed understanding of exactly what your customers want to hear.
Your organisation can benefit from a fully scalable solution across multiple sales forces, products and countries that gives you greater insight into your customer interactions and strategy effectiveness, yet with easier message delivery.

 Predicting a Better Future 

 

At the Financial Times Global Pharmaceutical and Biotech Conference this week, the keynote address was given by M. Chris Viehbacher, Chief Executive Officer of Sanofi-aventis.

In the context of global financial meltdown, three industry mega mergers, and the usual challenges facing ‘Big Pharma’ it was bound to be interesting to hear the perspective of an industry heavyweight such as Chris, who prior to Sanofi-aventis, was a member of the board of GSK, and President of its Pharmaceutical Operations in North America.

And what he thinks certainly will matter to Sanofi-aventis. As he describes the role of CEO “You’ve got your hands on the wheel, and you decide where to go”. Having been quoted in Forbes Magazine in its most recent issue, "Betting the farm and waiting for the next blockbuster is not going to work," in his FT keynote, Chris commented that whilst there was low growth for the industry in traditional markets, there was growth to be seen in emerging and non-traditional markets, and new models to explore, supported by a number of consumer ‘mega-trends’:

 

• An ageing population
• Increasing propensity of obesity and diabetes
• Increasing urbanization creating greater demand for medical services
• ‘Well being’ factors – like aesthetics and nutrition
• Time compression, and
• Communications and information technology

 

With this in mind, it was not surprising to see that he sees growth drivers for Sanofi-aventis including vaccines, diabetes, emerging markets, and OTC/OTX. In a sentence, Chris predicted “A much better next decade than the one we’ve just experienced”.

Chris expanded on this in a short VoxPop for PharmiWeb.com – see below.

 

 

PharmiWeb VoxPop : Jonathan Peacock, Novartis - Creating Value in Pharma

Jonathan Peacock, Chief Financial and Administration Officer of Novartis, gave a keynote address entitled ‘Creating Value in Pharma – the CFO’s Perspective’ at the Financial Times Global Pharmaceutical and Biotech Conference, which took place in London on November 17th and 18th.

Value creation is a continuous challenge within the pharma and biotech industry, made even more difficult with the current climate of cost reductions, M&A deals, and a declining ROI in R&D.

Peacock discussed the future trends and changes within the pharma and biotech industry with the unique insight and awareness of a CFO.

 New trends and changes highlighted by Peacock included:

• A more targeted therapy era taking over the recent blockbuster era - the move towards more specific and differentiated therapy areas, looking at subgroups of patients

• Growing patient influence with needs for better information and access to medicine

• An ageing population, resulting in the need for more healthcare treatment

• Poor health habits and sedentary lifestyles resulting in increasing of chronic diseases

• New technological discoveries allowing the development of innovative medicines

Other significant changes in the industry discussed by Peacock included the shift in influences with payers, patients and providers taking a more important role, and more focus on understanding patient needs and delivering outcomes for patients.

We were lucky enough to get a few minutes of Mr Peacock's time during the conference.

Click below to see Jonathan Peacock, Chief Financial and Administration Officer of Novartis talking to PharmiWeb.com about the future trends in pharma.